

# SURYA PHARMACEUTICAL LIMITED

REGD. OFFICE: 1596, 1st Floor, Bhagirath Palace, Chandni Chowk, Delhi - 110006 (INDIA)

## UNAUDITED (STANDALONE) FINANCIAL RESULTS FOR THE QUARTER ENDED DECEMBER 31, 2013

							Rs. In Lacs
Sr. No.	PART - I Particulars	Quarter ended			Nine Months Ended		Year Ended
		31.12.2013	30.09.2013	31.12.2012	31.12.2013	31.12.2012	31.03.2013
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Net Sales/Income from Operations (Net of Excise Duty)	57.22	458.23	1,001.72	1089.50	5651.56	6,033.04
	<b>Total</b>	<b>57.22</b>	<b>458.23</b>	<b>1,001.72</b>	<b>1,089.50</b>	<b>5,651.56</b>	<b>6,033.04</b>
2	Expenditure						
	a. (Increase)/Decrease in Stock in Trade and WIP, FG	57,180.49	665.79	630.87	58,476.87	(1,056.41)	9,093.01
	b. Consumption/Decrease in value of Raw Materials	4,124.35	(3.06)	690.65	4143.27	8919.35	9,192.61
	c. Purchase of Traded Goods	-	-	-	-	-	-
	d. Employees' benefits expense	86.98	34.53	196.03	171.23	847.72	884.51
	e. Depreciation/Amortisation	1,566.85	1,566.85	1,019.71	4700.55	2846.54	6,246.51
	f. Other Expenditure	374.14	76.97	372.22	631.23	1972.30	2,561.40
	<b>g. Total</b>	<b>63,332.81</b>	<b>2,341.08</b>	<b>2,909.48</b>	<b>68,123.15</b>	<b>13,529.50</b>	<b>27,978.04</b>
3	Profit from Operations before Other Income, Finance Costs & Exceptional Items (1-2)	(63,275.59)	(1,882.85)	(1,907.76)	(67,033.65)	(7,877.94)	(21,945.00)
4	Other Operating Income	3.02	-	3.41	3.02	100.18	(1,763.91)
5	Profit before Finance Costs & Exceptional Items (3+4)	(63,272.57)	(1,882.85)	(1,904.35)	(67,030.63)	(7,777.76)	(23,708.91)
6	Finance Costs	1,592.84	6,927.97	5,889.48	14,701.02	16,597.36	20,368.94
7	Profit after Finance Costs but before Exceptional Items (5-6)	(64,865.41)	(8,810.82)	(7,793.83)	(81,731.65)	(24,375.12)	(44,077.85)
8	Exceptional Items	21,917.43	-	-	21,917.43	-	-
9	Profit from Ordinary Activities before tax (7-8)	(86,782.84)	(8,810.82)	(7,793.83)	(103,649.08)	(24,375.12)	(44,077.85)
10	Tax expenses-Current Tax & Deferred Tax	-	-	-	-	-	14,419.04
11	Net Profit from Ordinary Activities after tax (9-10)	(86,782.84)	(8,810.82)	(7,793.83)	(103,649.08)	(24,375.12)	(29,658.81)
12	Extraordinary Items	-	-	-	-	-	1,792.95
13	Net Profit for the period (11-12)	(86,782.84)	(8,810.82)	(7,793.83)	(103,649.08)	(24,375.12)	(31,451.76)
14	Paid-up Equity Share Capital (Face Value of Rs.1/- per Share)	2,027.52	2,027.52	2,027.52	2,027.52	2,027.52	2,027.52
15	Reserves excluding Revaluation Reserves	-	-	-	-	-	(7,460.51)
16	Earnings Per Share (EPS)						
	a. Basic and diluted EPS before Extraordinary items	(42.80)	(4.35)	(3.84)	(51.12)	(12.02)	(15.51)
	b. Basic and diluted EPS after Extraordinary items	(42.80)	(4.35)	(3.84)	(51.12)	(12.02)	(15.51)

					Year Ended
PART - II		Quarter ended			31.03.2013
	Particulars	31.12.2013	30.09.2013	31.12.2012	
A	<b>PARTICULARS OF SHAREHOLDING</b>				
1	Public Shareholding				
	- Number of Shares	159713656	159713656	159713656	159713656
	- Percentage of Shareholding	78.77	78.77	78.77	78.77
2	Promoter and Promoter Group Shareholding:				
	a) Pledged/Encumbered				
	- No. of Shares	41869974	41869974	41869974	41869974
	- Percentage of Shares (as a % of the total shareholding of Promoter and Promoter Group)	97.28	97.28	97.28	97.28
	- Percentage of Shares (as a % of the total share Capital of the Company)	20.65	20.65	20.65	20.65
	b) Non-Encumbered				
	- No. of Shares	1168750	1168750	1168750	1168750
	- Percentage of Shares (as a % of the total shareholding of Promoter and Promoter Group)	2.72	2.72	2.72	2.72
	- Percentage of Shares (as a % of the total share Capital of the Company)	0.58	0.58	0.58	0.58

Particulars	3 months ended 31/12/2013
<b>B INVESTOR COMPLAINTS</b>	
Pending at the beginning of the quarter	0
Received during the quarter	1
Disposed of during the quarter	1
Remaining unresolved at the end of the quarter	0

For SURYA PHARMACEUTICAL LTD.

*Rajen Arora*

ED / M. GOYAL  
Managing Director

## Notes to Quarterly Results – Surya Pharmaceutical Limited

1. The above results were reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on February 14, 2014.
2. Certain creditors of the Company to whom amounts are due for payment (including certain claims wherein the amounts are partly or wholly disputed by the Company) have initiated proceedings for winding up of the Company before the jurisdictional High Court, i.e., Hon'ble Delhi High Court and/or proceedings for arbitration, inter alia, seeking interim relief from jurisdictional courts. The Company is contesting the above proceedings.

There exist orders for restrain issued by certain courts against the Company against disposal of assets/ specified assets by the Company. There are also orders for restrain and provisional attachment of properties of the Company issued by the Income tax Department. The Company has filed an application before the Settlement Commission to settle the demands and claims raised against the Company by the Income tax Department.

3. The Company has filed Reference under the Sick Industrial Companies (Special Provisions) Act, 1985 before the Hon'ble Board for Industrial and Financial Reconstruction for reasons of its accumulated losses as at March 31, 2013 exceeding its net worth.
4. Restructuring of debts of the Company carried by the lenders of the Company under Corporate Debts Restructuring Forum had been unilaterally recalled by certain lenders, which was followed, in some cases, by notice issued by lenders u/s 13(2) of the Securitisation and Reconstruction of Financial Assets and Enforcement of Security Interest Act, 2002 (SARFAESI). The Company, being aggrieved by the notice, filed a writ before the Hon'ble High Court of Jammu & Kashmir at Jammu, which had granted a stay against operation of abovesaid notices. However, four secured lenders of the Company have already withdrawn their notice issued u/s 13(2) of SARFAESI till the date of publication of this result.

The Company has suffered losses due to various illegal and unilateral actions by the banks and shall claim set off of damages and compensation against claim of the lenders, if any.

5. State Bank of India, as leader of the consortium of lenders of the Company, has filed an application under section 19 of the Recovery of Debts Due to Banks and Financial Institutions Act, 1993 before the Hon'ble Debt Recovery Tribunal at Chandigarh, seeking amongst others, an injunction against the Company from selling, disposing, transferring, alienating or creating any third party interest in the mortgaged properties and hypothecated assets of the Company. Aggrieved by an action of the said bank, the Company filed a writ petition before the Hon'ble High Court of Jammu and Kashmir at Jammu seeking quashing of above said proceeding, and the Hon'ble Jammu and Kashmir High Court was pleased to stay the Debt Recovery Tribunal proceedings vide its order dated 31.12.2013.
6. The Company was forced to suspend manufacturing activities at its various plants during the period from February 2012 to December 2012. The value of inventories comprising

FOR SURYA PHARMACEUTICAL LTD.

*Rajiv Goyal*

RAJIV GOYAL  
Managing Director

pharmaceutical products and its ingredients could not be put to use in a timely manner, amongst others, due to unilateral withdrawal of support by the banks during and post restructuring of Company's debts under CDR Forum, and the inventories have lost value due to efflux of time. The Company has made provision in its books of account for loss on account of impairment in value of inventories, which provisions, if required, will be reversed to the extent inventories are found capable of being put to use at any later date.

Pursuant to aforesaid withdrawal of sanctions by the lenders of the Company under CDR Forum, and following issuance of notice under section 13(2) of SARFAESI, several lenders of the Company issued public notice to customers of the Company calling upon them to pay the dues directly to the banks, and upon the aforesaid notice under SARFAESI having been stayed by the Hon'ble Jammu Bench of Jammu and Kashmir High Court, the public notice was not withdrawn by the said banks, resulting in recovery from customers getting sticky. The secured lenders have since withdrawn notice under section 13(2) of SARFAESI, and have not permitted the customers to make payment of outstanding to the Company, and that the lenders have yet to render account of amounts collected by them from Company's customers. The Company has transferred the amounts recoverable from its customers to a Provision for Debtors Account, accounted as a line item titled 'Exceptional Item' in the results set out above, and on rendering of accounts by the lenders the amounts so recovered by them shall be reversed out of the aforesaid account.

7. The Company's investment in its subsidiary companies is reviewed at each Balance Sheet date to consider impairment, if any, in value thereof which is other than temporary in nature. The results are stand alone for the Company and the results of the subsidiaries will be consolidated at the year end.
8. The above results have been reviewed by the Statutory Auditors of the Company.
9. The Company operates in only one segment.
10. Figures have been regrouped/rearranged wherever considered necessary.

**For and behalf of Board of Directors  
For Surya Pharmaceutical Limited**



**RAJIV GOYAL  
(Chairman & Managing Director)**

**Place: Chandigarh  
Date: 14<sup>th</sup> February, 2014**

# MSN & ASSOCIATES

## CHARTERED ACCOUNTANTS



### Delhi Office

G-1, Mezzanine Floor, Naurang House,  
21 K G Marg, Connaught Place,  
New Delhi - 110 001  
Phone: 91 11 43534898  
Fax: 91 11 43080505  
Mobile: 91 98180 89610  
www.msnandassociates.com

### Meerut Office

F-4, Tirupati Plaza  
Bachcha Park,  
Meerut (UP) - 250 002  
Phone: 91 121 4004427  
Fax: 91 121 4002639

### Limited Review Report

The Board of Directors  
M/s. Surya Pharmaceutical Limited  
1596, 1<sup>st</sup> Floor,  
Bhagirath Palace, Chandni Chowk,  
DELHI-110006

We have reviewed the accompanying statement of unaudited financial results of **M/s. Surya Pharmaceutical Limited** for the period ended **December 31, 2013** except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors/ Committee of Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, engagements to Review Financial Statements issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For MSN & Associates  
Chartered Accountants**



**Place: New Delhi  
Date: February 14, 2014**

**meet Jain  
FCA, Partner  
M. No. 98342**